These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15013927)

  • 1. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview.
    Toussirot E; Wendling D
    Expert Opin Pharmacother; 2004 Mar; 5(3):581-94. PubMed ID: 15013927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.
    Toussirot E; Wendling D
    Expert Opin Pharmacother; 2007 Sep; 8(13):2089-107. PubMed ID: 17714062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.
    Moreland LW
    Pharmacoeconomics; 2004; 22(2 Suppl 1):39-53. PubMed ID: 15157003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis.
    Hamilton K; Clair EW
    Expert Opin Pharmacother; 2000 Jul; 1(5):1041-52. PubMed ID: 11249494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
    Richard-Miceli C; Dougados M
    BioDrugs; 2001; 15(4):251-9. PubMed ID: 11437690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives for TNF-alpha-targeting therapies.
    Lorenz HM; Kalden JR
    Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S17-24. PubMed ID: 12110119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.
    Mikuls TR; Moreland LW
    Expert Opin Pharmacother; 2001 Jan; 2(1):75-84. PubMed ID: 11336570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.
    Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J
    Ann N Y Acad Sci; 2010 Apr; 1193():153-9. PubMed ID: 20398022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.
    Inanc N; Direskeneli H
    Rheumatol Int; 2006 Nov; 27(1):67-71. PubMed ID: 16896990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of anti-TNF-alpha molecules in inflammatory and infectious diseases].
    Fautrel B; Cherin P
    Rev Med Interne; 2000 Oct; 21(10):872-88. PubMed ID: 11075396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of tumor necrosis factor antagonism in clinical practice.
    Keystone EC
    J Rheumatol Suppl; 1999 May; 57():22-8. PubMed ID: 10328139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
    Koike R; Takeuchi T; Eguchi K; Miyasaka N;
    Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
    Feldmann M; Maini RN
    Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Paradigm shift in the treatment of rheumatoid arthritis by biologics].
    Tanaka Y
    Rinsho Byori; 2008 Apr; 56(4):309-15. PubMed ID: 18516965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.